Pharmacokinetics and safety of BCX9250, an ALK2 inhibitor for the potential treatment of Fibrodysplasia Ossificans Progressiva, following single and multiple doses of BCX9250 in healthy subjects
JOURNAL OF BONE AND MINERAL RESEARCH(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要